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A B S T R A C T
Objectives: Malaria treatment is impeded by increasing resistance to conventional antimalarial drugs.
Here we explored the activity of ten novel benzothiophene, thiophene and benzene aminoquinolines.
Methods: In vitro testing was performed by the lactate dehydrogenase assay in chloroquine (CQ)-sensitive
Plasmodium falciparum strain 3D7 and CQ-resistant (CQR) P. falciparum strain Dd2. In vivo activity was
evaluated by a modified Thompson test using C57BL/6 mice infected with Plasmodium berghei ANKA
strain.
Results: Nine of the ten compounds had a lower 50% inhibitory concentration (IC50) than CQ against the
CQR strain Dd2. Five of these compounds that were available for in vivo evaluation were shown to be non-
toxic. All five compounds administered at a dose of 160 mg/kg/day for 3 days prolonged the survival of
treated compared with untreated mice. Untreated control mice died by Day 7 with a mean parasitaemia
of 15%. Among treated mice, a dichotomous outcome was observed, with a two-third majority of treated
mice dying by Day 17 with a low mean parasitaemia of 5%, whilst one-third survived longer with a mean
hyperparasitaemia of 70%; specifically, five of these mice survived a mean of 25 days, whilst two even
survived past Day 31.
Conclusions: The significant antimalarial potential of this aminoquinoline series is illustrated by its
excellent in vitro activity against the CQR P. falciparum strain and significant in vivo activity. Interestingly,
compounds ClAQ7, ClAQ9 and ClAQ11 were able to confer resistance to cerebral malaria and afford a
switch to hyperparasitaemia to mice prone to the neurological syndrome.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Malaria is a parasitic infection caused by protozoa of the
genus Plasmodium that affects millions of people worldwide [1].
The resistance both of parasites and vectors to existing drugs is an
ongoing and increasing problem, hampering both prevention and
treatment of malaria. Indeed, Plasmodium parasites are develop-
ing resistance to nearly all conventional antimalarials, and
Anopheles vectors are becoming resistant to insecticides, with$ The results of this study were presented in part at the 14th International
Congress of Parasitology (ICOPA2018), 19–24 August 2018, Daegu, South Korea.
* Corresponding author.
E-mail address: olgicadj@imi.bg.ac.rs (O. Djurkovic-Djakovic).
http://dx.doi.org/10.1016/j.jgar.2020.07.027
2213-7165/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Soc
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).no vaccine existing to date. Additionally, climate changes and
migrations may favour further spread and the re-emergence of
malaria even in areas considered free of the disease. Given these
circumstances, discovering new antimalarial compounds that can
overcome parasite resistance has emerged as a global scientific
goal [2–7].
Our recent work focused on the antimalarial effect of 26 novel
aminoquinolines investigated in both in vitro and in vivo model
systems and showed a great potential of adamantane derivatives,
with two compounds shown to cure Plasmodium berghei-infected
mice [8]. The current study examined ten novel benzothiophene,
thiophene and benzene derivatives of the same aminoquinoline
series, whose synthesis has recently been described [9–11]. Here
we report on the activity of these ten aminoquinolines in different
in vitro model systems as well as in vivo and note that someiety for Antimicrobial Chemotherapy. This is an open access article under the CC BY-
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parasitaemia of mice prone to the neurological syndrome.
2. Materials and methods
2.1. Parasites
For in vitro drug assays, chloroquine (CQ)-sensitive (CQS)
Plasmodium falciparum strain 3D7 and CQ-resistant (CQR) P.
falciparum strain Dd2 were used. Cell cultures were maintained
as described previously [12]. Parasites were synchronised with 5%
sorbitol and ring-stage parasites were seeded in 96-well plates to
achieve 2% parasitaemia and 0.75% haematocrit.
For in vivo testing, P. berghei ANKA strain maintained through
serial intraperitoneal (i.p.) passage in C57BL/6 mice was used.
2.2. Mice
Female C57BL/6 mice (Medical Military Academy Animal
Research Facility, Belgrade, Serbia) weighing 19–21 g were used.
Mice were housed in groups of four to six animals in the Institute
for Medical Research Animal Facility under a natural photoperiod
and were offered drinking water and standard feed ad libitum.
2.3. Compounds
Ten novel aminoquinoline derivatives with chemical modifi-
cations at the aminoquinoline moiety and side chain, synthesised
at the Faculty of Chemistry, University of Belgrade [9–11], were
examined (Table 1). According to the structure of the amino-
quinoline moiety, compounds were classified into 4-aminoquino-
lines (AQs) (two compounds) and 7-chloro-4-aminoquinolines
(ClAQs) (eight compounds).
For experimental use in vitro, compounds were dissolved in
dimethyl sulfoxide (DMSO) at a stock concentration of 50 mM.
Compounds were further diluted in complete RPMI 1640 culture
medium and the final DMSO concentration was 0.2%.
For in vivo experiments, compounds were suspended in 0.5%
hydroxyethyl cellulose/0.1% Tween 80 and were administered
orally (p.o.).
2.4. Experimental design
All compounds were screened in vitro and, if appropriate, were
titrated to obtain 50% inhibitory concentration (IC50) values and
examined for antimalarial efficacy in vivo. Prior to in vivo
evaluation of the selected compounds, all were tested for toxicity
in mice.Table 1
Compounds grouped according to modifications at the aminoquinoline moiety.













In vitro evaluation of the antimalarial activity of the compounds
was performed using the colorimetric lactate dehydrogenase assay
[13]. Compounds were first screened at a concentration of 500 nM
(three replicates per compound for each P. falciparum strain) and
those that showed a minimum of 50% parasite growth inhibition
were further titrated to determine their IC50 value. CQ was used as
a positive control. Briefly, compounds were titrated using eight
two-fold dilutions, starting at a concentration of 256 nM or
1000 nM, depending on the results of the initial screening. Three
independent experiments were performed for each compound,
with three replicates per compound for each P. falciparum strain.
More precisely, the IC50 value of each compound and CQ was
calculated as the geometric mean IC50 value of the individual
experiment for a particular strain of P. falciparum.
In vivo toxicity of the experimental compounds was examined
through a series of experiments in which selected compounds
were administered at a dose of 160 mg/kg/day p.o. to healthy mice
during 3 consecutive days. Mice were monitored daily over a
period of 30 days for survival and appearance of symptoms
indicating toxicity such as ruffled fur, lethargy, loss of appetite,
lacrimation, salivation, diarrhoea, convulsions and weight loss.
Compounds not causing signs of gross toxicity were included in
further investigations.
The in vivo antimalarial activity of the non-toxic compounds
was evaluated by a modified Thompson test [14]. Mice were
infected i.p. with 106 infected erythrocytes in phosphate-buffered
saline (PBS) (250 mL total volume) obtained from the peripheral
blood of a P. berghei. ANKA-infected donor mouse; this time point
was considered Day 0. Mice were treated with investigational
compounds once a day for 3 consecutive days on Days 3, 4 and 5
post-infection. All compounds were administered p.o. at a dose of
160 mg/kg/day (200 mL total volume) in accordance with previous
experience of both our and other groups [5,15]. Infected mice
treated with the same dose of CQ served as a positive control
group, whereas untreated infected mice served as a negative
control group. Survival and parasitaemia were monitored for 30
days post-infection.
Parasitaemia was monitored by microscopic examination of
Giemsa-stained peripheral blood smears using mouse tail blood
twice a week, starting immediately before the initiation of
treatment (Day 3 post-infection). Up to 1000 erythrocytes were
counted and parasitaemia was calculated. The sample obtained
immediately before treatment initiation was of particular impor-
tance. Blood smears positive for P. berghei parasites presented
evidence that mice were infected to a degree that would allow
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the experiment.
Compound efficacy was evaluated on the basis of survival of
treated versus untreated mice as assessed both by the rate and
length of survival (expressed in % and days, respectively) and the
presence and level of parasitaemia over time. Cure was defined as
survival past Day 31 p.i. and clearance of parasitaemia.
2.6. Statistical analysis
IC50 values were obtained using a sigmoidal dose–response
model with the variable slope fitted to the results. The rates of
survival in particular groups were estimated by the Kaplan–Meier
product limit method and were compared by the log-rank (two
curves) and log-rank for trends (three or more curves) tests. The
level of statistical significance was 0.05. All statistics was
performed using GraphPad Prism (GraphPad Software Inc., La
Jolla, CA, USA).
3. Results
A series of ten novel aminoquinolines with modifications at the
linker and at the quinoline nucleus was examined both in vitro and
in vivo for antimalarial efficacy. At a concentration of 500 nM, eight
(AQ4, AQ5, ClAQ9–ClAQ13 and ClAQ15) of the ten compounds
inhibited the growth both of the CQS and CQR P. falciparum strain by
50%, whilst one (ClAQ7) exerted this effect only against the CQR
strain (Fig. 1). When titrated to determine IC50 values, all nine
compounds were more active than CQ against the CQR strain,
whilst none performed better than CQ against the CQS strain
(Table 2). Although all of these nine compounds qualified for
further examination, four (AQ4, AQ5, ClAQ10 and ClAQ12) were
unavailable due to technical reasons (not synthesised in sufficient
quantity).
The five available compounds (ClAQ7, ClAQ9, ClAQ11, ClAQ13
and ClAQ15) were first assayed for toxicity. No gross toxicity was
noted in any mice given any of the compounds at a dose of 160 mg/
kg/day, and all five compounds were thus subjected to in vivo
testing. Prior to treatment administration, all mice were checked
for parasitaemia; the pre-treatment parasitaemia was 0.7  0.4% in
mice assigned to the negative control group and 0.6  0.3% in those
assigned to treatment (P > 0.05). The results showed that
compared with untreated control animals that died after
7.3  0.5 days, treatment with all five investigational compounds
significantly (P < 0.05) prolonged the length of survival (Table 2) to
a mean of 17.7  5.3 days for the 23 mice that died during the
experiment. However, comparative analysis of the efficacy of the
compounds showed different levels of activity (Fig. 2). Compounds
ClAQ9 and ClAQ13 afforded survival of one mouse each (out of fourFig. 1. In vitro activity of ten novel compounds against two Plasmodium falciparum st
falciparum strain Dd2. Three replicates per compound were performed for each P. falciand five, respectively) past Day 31, but with high parasitaemia as
observed on blood smears, whilst the mice that died survived
17.3  0.6 days and 14.75 1.7 days, respectively. On the other
hand, compounds ClAQ7, ClAQ11 and ClAQ15 did not afford
survival of any mice but prolonged length of survival of treated
animals to 18.6  8.05, 18.6  7.6 and 18.3  3.4 days, respectively
(Table 2).
Regular monitoring of parasitaemia in each animal throughout
the entire experiment allowed for several interesting observations
(Tables 2 and 3). In untreated control mice at the time of death,
parasitaemia ranged between 11.8% and 17.3% (mean 14.8  2.3%).
In contrast, the mean parasitaemia of the treated animals that died
by Day 17 (n = 16; mean survival 14.8  2.5 days) was only
4.8  3.5%. Another two animals (both treated with ClAQ15)
survived to Day 21 and Day 24, respectively, with a mean
parasitaemia of 7.8  3.3%, also significantly (P < 0.05) below that
of the control mice. On the other hand, all other animals lived
longer (five dying between Days 21 and 28, with a mean survival of
25  4 days, and two still alive at Day 31), with a mean parasitaemia
of 70  10.5%.
4. Discussion
The results presented here demonstrate a significant antima-
larial potential of the examined aminoquinoline series. Nine of the
ten compounds were more active than CQ against the CQR P.
falciparum strain Dd2. Moreover, a significant biological activity of
five compounds (ClAQ7, ClAQ9, ClAQ11, ClAQ13 and ClAQ15)
against P. berghei was shown. Whereas all five compounds
significantly prolonged the length of survival compared with
untreated infected animals, two compounds afforded survival up
to Day 31 of 1/4 (ClAQ9) and 1/5 (ClAQ13) treated mice, albeit with
residual parasitaemia.
All five examined compounds that exhibited significant in vivo
activity share the same AQ nucleus with a chlorine atom at the C(7)
position. It is known that the AQ ring is required for complexation
with ferriprotoporphyrin but is not sufficient for the inhibition of
haemozoin synthesis [16]. A chlorine atom at position C(7) is
introduced into the AQ molecule for this purpose [16–19], and the
present results confirm its role. Benzothiophene ClAQ9 is one of
the two compounds that afforded survival (if only of one mouse)
past Day 31. In our recent investigations of another series of novel
aminoquinolines, two benzothiophenes were among the most
effective compounds [8], whilst another afforded cure [11]. Taken
together, these results illustrate the significance of the benzo-
thiophene structure introduced in the side chain of aminoquino-
lines. Benzothiophene is suitable for the synthesis of large
bioactive molecules owing to its heterocyclic structure, whilst
the wide range of pharmacological activities (over 40) of this ringrains, chloroquine-sensitive P. falciparum strain 3D7 and chloroquine-resistant P.
parum strain. LDH, lactate dehydrogenase.
Table 2
Antimalarial effect of experimental aminoquinolines examined in vitro and in vivo.
Compound group/compound In vitro (LDH assay) In vivo (Thompson test), treatment with 160 mg/kg/day orally during 3 days (Days 3, 4 and 5 p.i.)
GM IC50 (nM)
3D7a Dd2b No. of mice dead





AQ4 18.77 73.35 N/A
AQ5 119.58 71.52 N/A
7-Chloro-4-aminoquinolines




0/5 Prolonged time to deathc
ClAQ9 82.35 186.79 2 D17,
1 D18
1/4 Prolonged time to deathc (3/4);
survivald (1/4)
ClAQ10 50.23 18.57 N/A





0/5 Prolonged time to deathc
ClAQ12 32.2 40.82 N/A




1/5 Prolonged time to deathc (4/5);
survivald (1/5)





0/6 Prolonged time to deathc
Chloroquine (control) 18.63 270.57 0 5/5 Cure
LDH, lactate dehydrogenase; GM, geometric mean; IC50, 50% inhibitory concentration; p.i., post-infection; d, day; N/A, not available.
a Chloroquine-sensitive Plasmodium falciparum strain 3D7.
b Chloroquine-resistant P. falciparum strain Dd2.
c Versus infected untreated (control) mice that died 7.33  0.48 days p.i.
d With residual parasitaemia.
Fig. 2. Effect of a 3-day oral treatment with 160 mg/kg/day of chloroquine (CQ) and five investigational compounds (ClAQ7, ClAQ9, ClAQ11, ClAQ13 and ClAQ15) on the survival
of mice (n = 5 per compound, except for ClAQ9 and ClAQ15 where there were 4 and 6 mice, respectively) infected with Plasmodium berghei ANKA strain. The blue box indicates
treatment days.
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the many benzothiophene activities [21], in vitro antimalarial
activity has recently been shown for benzothiophene-2-carbox-
amide [22] and bromobenzothiophene carboxamide derivatives
[23], which were also active in vivo.
The observation of the different levels of parasitaemia
associated with early or late death (and occasional survival with
parasitaemia in the range from 70–90% defined ashyperparasitaemia [24]), as the end result of treatment with
compounds ClAQ7, ClAQ11 and ClAQ9, respectively (Table 3),
deserves consideration. The C57BL/6 mouse strain is highly
susceptible to the neurological syndrome with an incidence of
cerebral malaria ranging from 60–100%, and mice die with low
parasitaemia (on average < 15%) within 6–10 days after being
challenged with 106 P. berghei ANKA blood-stage parasites [24].
On the other hand, in cerebral malaria-resistant mouse strains,
Table 3
Parasitaemia in individual Plasmodium berghei-infected mice treated orally with five experimental compounds (160 mg/kg/day) and in positive (CQ) and negative (untreated
infected) control groups at various sampling points.
Compound Parasitaemia (%) Mouse
Before treatment Day 7 Day 10 Day 14 Day 17 Day 21 Day 24 Day 28
ClAQ7 0.4 0.2 5.3 Death d12 1
0.4 0.3 2.9 4 4.6 57 Death d24 2
0.2 0.2 0.3 6.9 Death d15 3
1 0.2 2.7 5 9.3 55.2 82 86 4
0.7 0.2 7 Death d12 5
ClAQ9 0.4 0.4 0.5 0.7 Death d17 1
0.6 0.2 0.3 0.5 1.5 2.7 52 72 2
0.5 0.3 0.4 0.5 Death d17 3
0.5 0.4 0.6 0.8 3.7 Death d18 4
ClAQ11 0.4 6.6 13.5 47 60 Death d20 1
0.3 0.2 9.2 Death d13 2
0.2 9 Death d9 3
0.6 10 15 23.4 53.2 70 Death d23 4
0.4 8.9 12 12.8 50 64 75 Death d28 5
ClAQ13 0.3 0 0.1 n.s. 5.1 17.1 n.s. n.s. 1
1.1 0 1.1 n.s. Death d15 2
n.s. n.s. n.s. n.s. Death d17 3
n.s. n.s. n.s. Death d13 4
n.s. n.s. n.s. Death d14 5
ClAQ15 1.1 0 0.1 n.s. 0.5 10.1 Death d24 1
1.6 0 1.2 n.s. 5.5 Death d21 2
n.s. n.s. n.s. n.s. Death d15 3
n.s. n.s. n.s. n.s. Death d16 4
n.s. n.s. n.s. n.s. Death d17 5
n.s. n.s. n.s. n.s. Death d17 6
CQ 0.6 0 0 0 0 0 0 0 1
0.8 0 0 0 0 0 0 0 2
0.4 0 0 0 0 0 0 0 3
0.9 0 0 0 0 0 0 0 4
0.7 0 0 0 0 0 0 0 5
Untreated infected mice 1 17.3, Death d7 1
0.5 Death d7 2
0.9 Death d7 3
0.4 15.1 Death d8 4
0.3 15.2 Death d8 5
0.2 Death d7 6
1.2 Death d7 7
1.2 11.8 Death d8 8
0.9 Death d7 9
d, day; n.s., not sampled.
Fig. 3. Example of peripheral blood smear at Day 24 post-infection showing
hyperparasitaemia in Plasmodium berghei-infected C57BL/6 mouse treated with
ClAQ11 (Giemsa staining, light microscope, magnification 1000).
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infection due to anaemia caused by hyperparasitaemia [24].
However, delayed death associated with hyperparasitaemia in P.
berghei-infected mice owing to pharmacological treatment or
genetic background has been observed [25,26]. In our study,
untreated infected animals died on average after 7.3 days, with a
parasitaemia of 14.8%, exactly in line with the study by Bagot et al.
[24]. In contrast, the investigational compounds all significantly
prolonged survival, with a mean survival of mice that died during
the experiment of 17.7 days. Among the mice treated with all five
compounds, despite high variability within particular treatment
groups, the animals clearly segregated into roughly a two-third
majority that died within the first 17 days (mean 14.8 days) with a
low parasitaemia of 5%, and one-third that survived a mean of 25
days with a mean parasitaemia of 70% (Fig. 3). It stands to reason
that the first developed cerebral malaria as expected in P. berghei-
infected C57BL/6 mice, but with a delay, whereas those that died
at later times succumbed to anaemia caused by hyperparasitae-
mia. Hence, the results presented herein indicate that the
compounds afforded prevention of cerebral malaria or a delay
J. Srbljanovic et al. / Journal of Global Antimicrobial Resistance 23 (2020) 20–25 25in its development in a mouse strain susceptible to cerebral
malaria.
One limitation of this study is that we have not studied the
residual parasite populations in mice that survived to the end of
the experiment with a hyperparasitaemia of up to 86%, which
could have shed more light on their virulence and pathogenicity.
However, this was not possible since microscopic examination of
the blood smears was not performed immediately following the
sampling because of the large number of blood smears, and the
residual parasites were not preserved.
In conclusion, this series of aminoquinolines exhibited signifi-
cant antimalarial activity. Excellent in vitro activity against the CQR
strain of even nine of the ten compounds is highly relevant, since
the primary goal of new treatment options is to overcome parasite
resistance. Interestingly, several compounds conferred resistance
to cerebral malaria to mice prone to the neurological syndrome, an
observation that merits further investigation.
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